Veracyte (VCYT) Tops Q3 EPS by 2c
Get Alerts VCYT Hot Sheet
Join SI Premium – FREE
Veracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $19.55 million.
“We delivered a solid performance this quarter in which we grew our genomic test volume, despite the impact of the hurricanes in key markets, further expanded reimbursement and booked our first Perceptarevenue,” said Bonnie Anderson, Veracyte\'s chairman and chief executive officer. “We believe our strong foundation to drive revenue growth is in place and we are encouraged by the increased momentum we began to see towards the end of the quarter. This included the increase in new Afirma Genomic Sequencing Classifier (GSC) accounts, adoption of Afirma GSC by Quest/Ameripath physicians and an expanded sales force in place.”
For earnings history and earnings-related data on Veracyte (VCYT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- MillerKnoll, Inc. (MLKN) Tops Q3 EPS by 1c; offers Q4 guidance
- Rex American Resources Corp. (REX) Tops Q4 EPS by 48c
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!